Buprenorphine-Induced Antinociception Is Mediated by μ-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors

Journal of Neuroscience

Volumn 23, Issue 32, 2003, Pages 10331-10337

  Lutfy, Kabirullah ^a,e   Eitan, Shoshana ^a   Bryant, Camron D ^a   Yang, Yu C ^a   Saliminejad, Nazli ^a   Walwyn, Wendy ^a   Kieffer, Brigitte L ^b   Takeshima, Hiroshi ^c   Carroll, F Ivy ^d   Maidment, Nigel T ^a   Evans, Christopher J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d RTI INTERNATIONAL   (United States)

^e WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Antinociception; Buprenorphine; Etorphine; J 113397; Knock out mice; MAP kinase; Morphine; ORL 1 receptors; Orphanin FQ nociceptin; Tail flick assay; opioid receptors

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; BUPRENORPHINE; MITOGEN ACTIVATED PROTEIN KINASE; MORPHINE; MU OPIATE RECEPTOR; NOCICEPTIN; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; PROTEIN KINASE B;

ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST;

EID: 0345687444     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-32-10331.2003     Document Type: Article

References (48)

1. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S (2000) Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21:1141-1146.
2. Bodkin JA, Zornberg GL, Lukas SE, Cole JO (1995) Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 15:49-57.
3. Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M, Grandy DK (1994) Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett 347:284-288.
4. Chen Y, Fan Y, Liu J, Mestek A, Tian M, Kozak CA, Yu L (1994) Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett 347:279-283.
5. Compton PA, Ling W, Charuvastra VC, Wesson DR (1995) Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. J Addict Dis 14:97-114.
6. Cowan A (1995) Up date of the general pharmacology of buprenorphine. In: Buprenorphine: combating drug abuse with a unique opioid (Lewis J, Cowan A, eds), pp 31-47. New York: Wiley.
7. Cowan A, Lewis JW, Macfarlane IR (1977a) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545.
8. Cowan A, Doxey JC, Harry EJ (1977b) The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 60:547-554.
9. Derbyshire SW, Jones AK, Gyulai F, Clark S, Townsend D, Firestone LL (1997) Pain processing during three levels of noxious stimulation produces differential patterns of central activity. Pain 73:431-445.
10. Dum J, Blasig J, Herz A (1981) Buprenorphrine: demonstration of physical dependence liability. Eur J Pharmacol 70:293-300.
11. Finco G, Polati E, Gottin L, Bartoloni A, Milan B, Zanoni L, Valle L (1995) Intravenous patient-controlled analgesia (PCA) in the treatment of post-operative pain: rationale and clinical application. Chir Ital 47:20-25.
12. Fukuda K, Kato S, Mori K, Nishi M, Takeshima H, Iwabe N, Miyata T, HoutaniT, Sugimoto T (1994) cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett 343:42-46.
13. Hawkinson JE, Acosta-Burruel M, Espitia SA (2000) Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur J Pharmacol 389:107-114.
14. Heel RC, Brogden RN, Speight TM, Avery GS (1979) Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 17:81-110.
15. Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695.
16. Jacob JJ, Ramabadran K (1978) Enhancement of a nociceptive reaction by opioid antagonists in mice. Br J Pharmacol 64:91-98.
17. Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35:501-516.
18. Johnson RE, McCagh JC (2000) Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep 2:519-526.
19. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, Devi LA (2001) Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 98:343-348.
20. Kaufman DL, Keith Jr DE, Anton B, Tian J, Magendzo K, Newman D, Tran TH, Lee DS, Wen C, Xia Y-R, Lusis AJ, Evans CJ (1995) Characterization of the murine mu opioid receptor gene. J Biol Chem 70:15877-15883.
21. Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y (1999) Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R, 4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J Med Chem 42:5061-5063.
22. Keith Jr DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
23. Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20:19-26.
24. Leander JD (1988) Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol 151:457-461.
25. Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14:363-372.
26. Lewis JW, Walter D (1992) Buprenorphine-background to its development as a treatment for opiate dependence. NIDA Res Monogr 121:5-11.
27. Ling W, Wesson DR, Charuvastra C, Klett CJ (1996) A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53:401-407.
28. Ling W, Charuvastra C, Collins IF, Batki S, Brown Jr LS, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner Jr JA, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D (1998) Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93:475-486.
29. Litten RZ, Allen JP (1999) Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings. J Subst Abuse Treat 16:105-112.
30. Lizasoain I, Leza JC, Lorenzo P (1991) Buprenorphine: bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol 22:297-300.
31. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532.
32. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819-823.
33. Mello NK, Mendelson JH, Lukas SE, Gastfriend DR, Teoh SK, Holman BL (1993) Buprenorphine treatment of opiate and cocaine abuse: clinical and preclinical studies. Harv Rev Psychiatry 1:168-183.
34. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazarguil H, Vassart G, Parmentier M, Costentin J (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532-535.
35. Mogil IS, Pasternak GW (2001) The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53:381-415.
36. Mogil JS, Grisel JE, Zhangs G, Belknap JK, Grandy DK (1996) Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci Lett 214:131-134.
37. Mollereau C, Parmentier M, Mailleux, P, Butour JL, Moisand C, Chalon P, Caput D, Vassart G, Meunier JC (1994) ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341:33-38.
38. Nishi M, Houtani T, Noda Y, Mamiya T, Sato K, Doi T, Kuno J, Takeshima H, Nukada T, Nabeshima T, Yamashita T, Noda T, Sugimoto T (1997) Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J 16:1858-1864.
39. Picard PR, Tramer MR, McQuay HJ, Moore RA (1997) Analgesic efficacy of peripheral opioids (all except intra-articular): a qualitative systematic review of randomised controlled trials. Pain 72:309-318.
40. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma Jr FJ, Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270:792-794.
41. Reynaud M, Petit G, Potard D, Courty P (1998) Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93:1385-1392.
42. Rothman R, Qi NI, Xu H (1995) Buprenorphine: a review of the binding literature. In: Buprenorphine: combating drug abuse with a unique opioid (Lewis J, Cowan A, eds), pp 19-30. New York: Wiley.
43. Sadee W, Rosenbaum IS, Herz A (1982) Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 223:157-162.
44. Takita K, Morimoto Y, Kemmotsu O (2003) Role of nociceptin/orphanin FQ and nociceptin/orphanin FQ peptide receptor in respiratory rhythm generation in the medulla oblongata: an in vitro study. Br J Anaesth 91:385-389.
45. Tyers MB (1980) A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol 69:503-512.
46. Tzschentke TM (2002) Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl) 161:1-16.
47. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569-580.
48. Wnendt S, Kruger T, Janocha E, Hildebrandt D, Englberger W (1999) Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol 56:334-338.